Woman Claims Liver Failure, Organ Damage After Using Mounjaro For Weight Loss
Quick Read
Summary is AI generated, newsroom reviewed.
A 34-year-old UK woman, Aimee Chapman, faced life-threatening complications, including a perforated oesophagus and liver failure, after using the weight-loss drug Mounjaro bought online. Her case highlights risks of unsupervised weight-loss drug use.
A 34-year-old woman from Southampton, UK, has claimed she suffered life-threatening complications after using a weight-loss drug she purchased online. Aimee Chapman, who lost over 25 kilograms while taking Mounjaro- a drug increasingly popular for weight management- was later admitted to intensive care with a perforated oesophagus and liver failure, conditions that doctors reportedly linked to the medication, Daily Mail reported.
Chapman, a former waitress diagnosed with fibromyalgia, said she turned to Mounjaro in March 2024 after struggling to find effective medical support for her chronic pain. She believed losing weight would help her be taken more seriously by healthcare professionals.
Initially, the medication appeared effective- she shed around four stone (roughly 25 kg) within four months. However, she soon began experiencing fatigue, nausea, and frequent vomiting. "I was throwing up all the time, sometimes vomiting blood-up to 60 times," she told The Daily Mail. "I collapsed a couple of times. My husband once found me passed out in the hallway."
As her condition worsened, she was rushed to Winchester Hospital's emergency department after developing severe chest pain. Doctors found a hole in her oesophagus, a rare and serious condition that allowed air to leak into the chest cavity around her heart and lungs.
She was later transferred to the intensive care unit at Southampton General Hospital, where doctors noticed signs of liver failure and considered her for a transplant. Her blood pressure and potassium levels had dropped sharply. "They said it was linked to the weight-loss injection, but didn't know exactly how or why," she said.
The incident highlights growing concerns about the unsupervised use of weight-loss drugs, particularly those purchased online without proper medical guidance. Mounjaro, originally developed to manage type 2 diabetes, has gained popularity for its weight loss effects, but experts have repeatedly warned of potential side effects when used without prescription or monitoring.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
11 hours ago
- Hindustan Times
Happy birthday Meryl Streep: Know her no 1 beauty secret for glowing skin at 76 that costs absolutely nothing
Meryl Streep turns 76 on June 22. The veteran Hollywood actor's 'one' beauty secret, as shared with British journalist Fi Glover on her Fortunately podcast, and reported in an October 17, 2017 Daily Mail report, is quite simple yet effective: she avoids touching her face. Also read | What Sharmila Tagore does for 'radiant, naturally glowing skin' at 79: Her top 3 traditional Indian skincare ingredients Meryl Streep was honored with the honorary Palme d'Or at the opening ceremony of the 77th Cannes Film Festival, (File Photo/ AFP) Meryl Streep's approach to skincare emphasises prevention and gentle care, which can be beneficial for maintaining healthy, youthful-looking skin. But before we get into the benefits of not touching your face, here's what Fi Glover had said in her Fortunately podcast recalling how she once had the chance to chat with Meryl at a dinner party: 'Do you know what Meryl told me that evening? She said that her one beauty secret was never to touch her face. She never touches her face.' In a December 2015 report on Dr Ruth Tedaldi, a dermatologist, shared why it's a good idea to not touch facial skin. She said, 'When you're touching your face, there is a tendency to scan for irregularities and then a compulsion to pop or pick at anything undesirable. By picking at blemishes, you run a very high risk of worsening it. You can even cause acne scarring, which carries lifelong damage that can only be treated with special remedies.' She added, 'As reported by the US National Institutes of Health, people touch their faces an average of 3.6 times per hour. Our hands come in contact with millions of germs via smartphones, doorknobs, shoelaces, and more. Don't let these germs make it to your face, as this can lead to an unwanted acne breakout.' In an April 25, 2025 interview with HT Lifestyle, Dr Ameesha Mahajan, cosmetic dermatologist and founder, EdenSkinClinic, had also shared why avoiding touching your face is a must for healthy skin. According to her, 'It sounds simple, but touching your face can transfer dirt, bacteria, and oil, leading to clogged pores and pimples. This includes picking or popping zits, which can worsen inflammation and lead to scarring. Keep your hands clean and off your face as much as possible.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Economic Times
a day ago
- Economic Times
Eli Lilly says its anti-obesity pill matches Ozempic
New Delhi: Eli Lilly said on Saturday that its anti-obesity pill, Orforglipron, has shown significant results during clinical trials in reducing weight and lowering blood sugar in diabetes patients, comparable to Novo Nordisk's anti-diabetes drug Ozempic. The US drug maker aims to submit the Phase-III trial data to regulators by the end of this year and expects to get regulatory approvals from 2026, it said. The results were announced at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. Eli Lilly also makes blockbuster drug Tirzepatide for type-2 diabetes under the Mounjaro brand and chronic weight management under the brand Zepbound. Both are administered via injection. Orforglipron as well as Tirzepatide are GLP-1 drugs, which mimic a natural gut hormone that controls sugar levels and appetite. The 40-week trial of the new pill tested three doses of Orforglipron: 3 milligrams, 12 milligrams and 36 milligrams. All were found to be effective at lowering blood sugar, the company said. The 12 mg and 36 mg doses also showed clinically meaningful and statistically significant reductions in body weight compared to a placebo, the company said. The 36 mg dose led to an average weight loss of 7.9% over 40 weeks.
Time of India
a day ago
- Time of India
Eli Lilly says its anti-obesity pill matches Ozempic
Eli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling Novo Nordisk's Ozempic. The company plans to submit Phase-III trial data to regulators by year-end, anticipating approvals from 2026. The 36 mg dose resulted in an average weight loss of 7.9% over 40 weeks. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads New Delhi: Eli Lilly said on Saturday that its anti-obesity pill Orforglipron , has shown significant results during clinical trials in reducing weight and lowering blood sugar in diabetes patients, comparable to Novo Nordisk 's anti-diabetes drug Ozempic The US drug maker aims to submit the Phase-III trial data to regulators by the end of this year and expects to get regulatory approvals from 2026, it said. The results were announced at the annual meeting of the American Diabetes Association and published in the New England Journal of Lilly also makes blockbuster drug Tirzepatide for type-2 diabetes under the Mounjaro brand and chronic weight management under the brand Zepbound. Both are administered via as well as Tirzepatide are GLP-1 drugs , which mimic a natural gut hormone that controls sugar levels and 40-week trial of the new pill tested three doses of Orforglipron: 3 milligrams, 12 milligrams and 36 milligrams. All were found to be effective at lowering blood sugar, the company 12 mg and 36 mg doses also showed clinically meaningful and statistically significant reductions in body weight compared to a placebo, the company said. The 36 mg dose led to an average weight loss of 7.9% over 40 weeks.
